Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir for Long-COVID Prevention in Hospitalized Patients
NCT04978259Phase 4
Key facts
- Status
- Unknown
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Countries
- 1
- Sponsor
- Clinical Urology and Epidemiology Working Group
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- remdesivir
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of care plus remdesivir with Standard of care (2 arms). Primary endpoints: EuroQol Visual Analogue Scale at 1 year, EuroQol 5-Dimension 5-Level at 1 year and 4 more. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Standard of care plus remdesivir
Local standard of care plus daily remdesivir infusion for up to 10 days.
Standard of care
Local standard of care alone.
03
Who it enrols
Adults hospitalized with laboratory-confirmed SARS-CoV-2 infection, excluding those with severe renal or liver impairment, pregnancy, or life expectancy < 3 months.
04
Endpoints
Primary
EuroQol Visual Analogue Scale
EuroQol 5-Dimension 5-Level
Recovery from COVID-19 Infection
Fatigue
Exertional dyspnea
Secondary
EuroQol Visual Analogue Scale at 2 years
Beyond the preview
Go deeper on NCT04978259.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978259.